The ABBOTT PRISM system is intended for in vitro diagnostic use only. A high throughput, highly automated test system for blood ... operating electromechanical equipment and are responsible ...

Abbott’s device business has been a bright spot as litigation over its baby formula products and declining demand for its COVID tests have ... the Russian president machines when they were ...

Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests. Guidance: Abbott projects full-year 2025 ...

For full-year 2025, the company forecast organic sales growth between 7.5% and 8.5% as well as adjusted earnings per share in the range of $5.05 and $5.25. Analysts polled by FactSet expect $42 ...

“secretly sent Putin a bunch of Abbott Point of Care Covid test machines for his personal use” while the terrifying virus was shape-shifting, Americans were dying, and supplies were ...

Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong performance in medical devices.

Abbott Laboratories posted lower-than-expected sales in its latest quarter, dented in part by diminished demand for Covid-19 testing-related products. The healthcare-products manufacturer logged ...